September 19, 2021

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19

SHANGHAI, China, Sept. 19, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for etesevimab (JS016/LY-CoV016)

Read More

More field hospitals needed in Penang – Lim

GEORGE TOWN, Sept 19 — There is a need for more field hospitals to be set up in Penang to accommodate the increasing number of COVID-19 cases in the state, DAP secretary-general Lim Guan Eng said today.The Member of Parliament for Bagan said that Int…

Read More